ClinicalTrials.gg
Drug

Amikacin clinical trials

Also written ARIKAYCE® and Amikin.

studies test it
46
open now
7
in phase 3
10
first study started
2002

How each study uses Amikacin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Amikacin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Jan 1981 · AMIKIN · ANDA 062311 (FDA, Drugs@FDA)
European Union
27 Oct 2020 · Arikayce liposomal · EMEA/H/C/005264 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Amikacin
12
liposomal amikacin for inhalation
5
Amikacin Injection
4
ALIS
2
Amikacin liposome inhalation suspension
2

Brand

ARIKAYCE®
10
Amikin
2
Arikayce™ 560 mg
1
Arikayce™ 70 mg
1
Arikayce™ 140 mg
1

Studies by the year they started

43 studies that test it; most in 2012 (6); 1 more planned to start later

Studies that test Amikacin, by start year
YearStudies
20021
20043
20071
20082
20093
20101
20126
20142
20153
20164
20172
20181
20191
20204
20212
20231
20242
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
15
Phase 3
10
Phase 4
9
No phase
9

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 31

Insmed Incorporated (13) · Assistance Publique - Hôpitaux de Paris (2) · The University of Queensland (2) · Beni-Suef University (1) · Murdoch Childrens Research Institute (1) · Postgraduate Medical Institute, Lahore (1) · University Hospital, Tours (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)

Often tested with

Tested in the same studies.

Imipenem (5) · Clofazimine (4) · Ceftazidime (3) · Ciprofloxacin (3) · Colistinmethanesulfonic acid (2) · Meropenem (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2) · Piperacillin, Tazobactam Drug Combination (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Amikacin.

Studies

Open first, then newest update. How each study uses Amikacin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test Amikacin →

Given beside what is tested · 2 — Amikacin is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with Amikacin

Codes

What other systems call Amikacin · ClinicalTrials.gg INT006943

  • MeSH (NLM) D000583AmikacinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 84319SGC3CAMIKACINConfirmed FDA, NLM, Wikidata
  • RxNorm 641Confirmed FDA, Wikidata
  • Wikidata Q408529amikacinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61615AmikacinConfirmed FDA, Wikidata
  • DrugBank DB00479One source Wikidata

Also registered as amikacin sulfate (UNII N6M33094FD · RxNorm 643).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.